Abstract 427P
Background
Combination therapies (CT) are increasingly being developed and used in oncology. They have clinical benefits over and above monotherapies but face challenges in their assessment and pricing, which can delay or prevent access for patients in Asia-Pacific (AP) markets, especially when CTs consist of multiple on-patent constituents with different manufacturers. OHE conducted a study to understand the access landscape for CTs in AP and current access challenges (if any).
Methods
We extracted information on the regulatory approval and reimbursement decisions from the website of regulatory and HTA agencies, and drug listings of 14 free-dose CTs that received EMA marketing authorisation between 2015 and June 2020. All CTs included a constituent therapy that is licensed in another indication or CT. Markets in scope were Hong Kong, New Zealand, Singapore, South Korea and Taiwan. We developed a discussion guide for a series of interviews held by IQVIA with regulatory and HTA experts in the AP markets and analysed the transcripts to identify access challenges specific to CTs in individual markets.
Results
Only 6 out of 14 CTs of interest achieved access in any of the five AP markets. These comprised on-patent molecules produced by a single manufacturer or one on-patent molecule in combination with off-patent molecules. Barriers to access include anti-trust law impeding pricing negotiations between multiple manufacturers, monotherapy-centric focus of regulatory and reimbursement processes, issues with tracking usage by indication to facilitate indication-based pricing, and payers’ focus on budget impact over value assessment.
Conclusions
A multi-faceted collaborative approach by payers and manufacturers is needed with steps to tackle each barrier and improve patient access to CTs in AP.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Office of Health Economics.
Funding
MSD International GmbH.
Disclosure
G. Kumar, M. Garau, L. Steuten: Financial Interests, Institutional, Funding, This research was funded by MSD: Office of Health Economics. S.C. Tan, Y-R. Chen: Financial Interests, Institutional, Full or part-time Employment: MSD.
Resources from the same session
440P - Targeting KRAS<sup>G12C</sup>: Repurposing of potential therapeutics for the treatment of pancreatic ductal adenocarcinoma (PDAC)
Presenter: EVA RAHMAN KABIR
Session: Poster viewing 06
441P - Malignant diseases diagnosed in people living with HIV in Japan
Presenter: Kenju Ando
Session: Poster viewing 06
442P - Dose intensity and tolerance of modified FOLFIRINOX in patients with advanced cancer
Presenter: Tejaswini Adadadara
Session: Poster viewing 06
444P - Incidence of cancer diagnosis and cancer care before and after the COVID-19 pandemic in French Polynesia TEAHUPOO study
Presenter: Elodie HIRIGOYEN
Session: Poster viewing 06
445P - Development of a simple and objective prognostication model in patients with advanced solid malignant tumor treated with immune checkpoint inhibitors: A pan-cancer analysis
Presenter: Yuto Matsushita
Session: Poster viewing 06
446P - Impact of previous immunotherapy on chemotherapy efficacy in metastatic melanoma
Presenter: Meiyu Fang
Session: Poster viewing 06
447P - Clinical characteristics of 21 patients with type 1 diabetes mellitus related to immune checkpoint inhibitors
Presenter: Haruna Kameoka
Session: Poster viewing 06
448P - Prevalence of thyroid dysfunction, diabetes, and impact of palliative chemotherapy in advanced metastatic cancer patients: Prospective data from LMIC
Presenter: Amit Sehrawat
Session: Poster viewing 06
449P - The study of androgen receptor status in triple negative breast cancer patients at Medical Oncology Department, Yangon General Hospital (YGH)
Presenter: Khin Mu
Session: Poster viewing 06
450P - Are grade III well-differentiated neuroendocrine tumours a unique clinic-pathological entity?
Presenter: Jahnavi Kalvala
Session: Poster viewing 06